Paroxysmal Nocturnal Haemoglobinuria (PNH) Treatment Market - By Treatment (Stem cell transplantation, Blood transfusion, Medication) By End User (Hospitals, Clinics, Pharmaceutical and biotech companies, Academic & research institutes, Others) By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) - Industry Analysis, Opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 184
Status: Published
Report Code: ARI100726
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare blood disease of stem cells of the bone marrow that are genetically characterized by somatic mutation in the gene phosphatidylinositol glycan A (PIG-A). PNH occurs generally in the early 30's. At 21 years of age or earlier, around 10 per cent of patients develop PNH symptoms. In the U.S., it is estimated that around 1 to 5 individuals per million people suffer from PNH. This is significantly lower than bone marrow aplasia incidence rate. PNH often goes unrecognized; diagnostic delays can range from one year to over 10 years.
Complete stem cell transplantation is usually considered as life-threatening complications in severe cases of PNH, such as aplastic anaemia and transformation to leukemia. Factors driving the market for PNH treatment include an increase in the number of disorders related to blood & bone marrow, an increase in aging population and technological advances in stem cell transplantation. However, rising costs of medical equipment, specifically surgical equipment required for stem cell transformation; lack of reimbursement policies in developing regions; and occurrence of side effects in the related current treatments available may hamper the market for PNH treatments.
The global market for treating PNH may be segmented by treatment type and end-user. The demand for PNH treatment may be divided into Stem cell transplantation, Blood transfusion, and Prescription depending on the type of treatment. The PNH care market may be split into end-user-based hospitals, pharmaceutical & biotech companies, clinics, academic & research institutes, and others. Drugs are expected to show the highest growth over the forecast period followed by stem cell transplants and blood transfusions.
Geographically, the PNH treatment market can be broken down into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Due to the rise in the number of blood & bone marrow related diseases, the availability of adequate reimbursement policies and increased awareness of the early diagnosis of the disease in the region, North America dominates the global PNH treatment market. The European market is also expected to expand rapidly, as key players are working together with research institutions and laboratories to develop new, innovative products.
Analyst Commentary
The global market for treatment with PNH is expected to expand rapidly over the forecast period. It is a niche market, with many pharmaceutical and biotech firms investing in stem cell research for the bone marrow. The ideal treatment available is to replace all the hematopoietic stem cells with normal stem cells via stem cell transplantation, according to current studies. However, in some cases this treatment is not ideal, as stem cell transplantation requires a stable, histocompatibility donor.
Treatment strategy for PNH is changing rapidly. The advent of biologics which target causal hemolytic defects or abnormal hematopoietic stem cells is driving it. However, high therapy costs and surgical procedures such as stem cell transplants (SCT), unfavourable reimbursement environment in developing regions, and adverse side effects of available treatments may hinder market growth over the forecast period. In addition, for many patients’ stem cell transplants are not recommended since they are associated with significant morbidity and mortality.
Some Key Developments in the market are:
• Apellis Pharmaceuticals received the U.S. FDA Fast Track designation for APL-2, a novel drug for the treatment of adults with paroxysmal nocturnal hemoglobinura (PNH), in February 2020. This designation allows the company to work loose with the U.S. FDA and speeds up the review timelines that help patients get access to treatment as quickly as possible.
• In December 2018, Alexion Pharmaceuticals, Inc. obtained U.S. FDA approval for Ultomiris (ravulizumab) injection for paroxysmal nocturnal hemoglobinura (PNH) treatment in adults. Ultomiris approval provides a innovative treatment and important progress that offers full care for many of these patients.
Segmentation
The global market for PNH treatment can be segmented by type of treatment and end-user. Based on the type of treatment.
The allogeneic transplantation of stem cells is the only curative treatment for patients with PNH. Clinical results from different SCT programs show that this procedure is confined to a small number of patients suffering from similar rare disorders. Stem cell transplant treatment is recommended only for severe cases of PNH with life-threatening complications such as leukemia transformation or aplastic anaemia. Indications for SCT changed with the advent of Soliris.
Soliris is highly effective in the treatment of cases involving PNH associated with hemolysis. In 2007 the FDA approved the anti-complement monoclonal antibody, which works by targeting the component of the CD5 complement. It dramatically reduces symptom-related pain, such as easy bleeding, abdominal pain, dark urine, weakness, and fatigue, improves quality of life, and eliminates PNH complications.
Before Soliris' approval, blood transfusion was the only treatment choice which did not provide an adequate response. Approximately 35.0 per cent of patients died within five years of diagnosis, mainly due to fatal clots in vessels supplying vital organs. Biologics and transplants of stem cells are gaining impression in developing countries. Monoclonal antibodies are projected to show strong growth in the global market for treatment with PNH, followed by recombinant proteins and cyclic peptides, among various classes of drugs. During the forecast period, drugs are expected to show the highest growth followed by stem cell transplants and blood transfusions. Due to increased risks and the sub-optimal outcome of these procedural approaches, cell transplants and blood transfusion are expected to lose shares during the same period.
Some of the leading players are Roche, Akari Therapeutics, Alexion Pharmaceuticals, Ra Pharmaceuticals, Novartis Pharmaceuticals, Alnylam, Apellis Pharmaceuticals, Achillion Pharmaceuticals, Regeneron Pharmaceuticals.These companies are focused on developing effective PNH treatment for which the companies collaborate with research institutes and labs.
The PNH care market can be divided into hospitals, pharmaceutical & biotech firms, clinics, academic & research institutes and others, based on end-user.
Regional Analysis
With more than 35.0 per cent share in 2020, the U.S. dominated the market. It is expected to maintain its market position through 2027. Potential approval of promising pipeline drugs, high U.S. treatment costs and increased adoption of novel therapies will likely contribute to regional market growth. In the forecast period Japan is poised to post the highest CAGR. It has a market share of over 10.0 per cent in 2020, led by Germany and the UK. The seven major markets were at the forefront of the global arena, accounting for more than 85.0 percent of the 2020 total revenues.
During the same time the rest of the world (RoW) is projected to experience remarkable growth. This can be due to favourable legislation and increased acceptance in some developed and developing countries like South Korea, China, Brazil, Australia, Canada, Mexico, the United States of America and Saudi Arabia. However, high drug costs and a lack of guidelines for reimbursement and policy frameworks are anticipated to hamper growth prospects.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Component
2.3.1. Secondary Component
2.3.1.1. Preliminary data mining
2.3.2. Primary Component
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market
Chapter 5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
5.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share, By Treatment, 2015 - 2027 (USD Million)
5.1.1. Stem Cell Transplantation
5.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Blood Transfusion
5.1.2.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Medication
5.1.3.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027(USD Million)
6.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share, By End-User, 2015 - 2027 (USD Million)
6.1.1. Hospitals
6.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
6.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Clinics
6.1.2.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Pharmaceutical and Biotic Companies
6.1.3.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Academic and Research Institutes
6.1.4.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.5. Others
6.1.5.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.5.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Geography, 2015 - 2027(USD Million)
7.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Share, By Geography, 2015 - 2027(USD Million)
7.1.1. Market Type and projections, by Countries, 2015 - 2027 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2020 - 2027 (%)
Chapter 8. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027(USD Million)
8.1. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.2. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
8.1.3. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
8.1.4. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1.4.1. U.S. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.1.2. U.S. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
8.1.4.1.3. U.S. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
8.1.4.2. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.2.2. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
8.1.4.2.3. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
8.1.4.3. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
8.1.4.3.2. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
8.1.4.3.3. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
Chapter 9. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027(USD Million)
9.1. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.2. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
9.1.3. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
9.1.4. Europe Skin Care Types Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.4.1. Germany
9.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.1.2. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
9.1.4.1.3. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027(USD Million)
9.1.4.2. France
9.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.2.2. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
9.1.4.2.3. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027(USD Million)
9.1.4.3. UK
9.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.3.2. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
9.1.4.3.3. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027(USD Million)
9.1.4.4. Italy
9.1.4.4.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.4.2. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
9.1.4.4.3. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User 2015 - 2027(USD Million)
9.1.4.5. Spain
9.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.4.5.2. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
9.1.4.5.3. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027(USD Million)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market Type and projections, 2015 – 2027
9.1.4.6.2. Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
9.1.4.6.3. Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027(USD Million)
Chapter 10. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.2. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
10.1.3. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
10.1.4. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.4.1. India
10.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.1.2. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
10.1.4.1.3. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
10.1.4.2. China
10.1.4.2.1. Market Type and projections, 2015 - 2027(USD Million)
10.1.4.2.2. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
10.1.4.2.3. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
10.1.4.3. Japan
10.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.3.2. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
10.1.4.3.3. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027(USD Million)
10.1.4.4. South Korea
10.1.4.4.1. Market Type and projections, 2015 - 2027(USD Million)
10.1.4.4.2. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
10.1.4.4.3. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.4.5.2. Rest of Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027(USD Million)
10.1.4.5.3. Rest of Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
Chapter 11. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.2. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
11.1.3. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
11.1.4. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.4.1. GCC
11.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.1.2. GCC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
11.1.4.1.3. GCC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
11.1.4.2. South Africa
11.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.2.2. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
11.1.4.2.3. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.4.3.2. Rest of Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
11.1.4.3.3. Rest of Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
Chapter 12. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.2. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
12.1.3. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
12.1.4. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Countries, 2015- 2026 (USD Million)
12.1.5. Brazil
12.1.5.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.2. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
12.1.5.3. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
12.1.6. Argentina
12.1.6.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.6.2. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
12.1.6.3. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
12.1.7. Rest of South America
12.1.7.1. Market Type and projections, 2015 – 2027
12.1.7.2. Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By Treatment, 2015 - 2027 (USD Million)
12.1.7.3. Rest of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview, By End-User, 2015 - 2027 (USD Million)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2021
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Type development
Chapter 14. Key Vendor Analysis
14.1. Roche
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Product Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Akari Therapeutics
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Product Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Alexion Pharmaceuticals
14.3.1. Company overview
14.3.2. Financial performance
14.3.3. Product Benchmarking
14.3.4. Recent initiatives
14.4. Ra Pharmaceuticals
14.5. Novartis Pharmaceuticals
14.6. Alnylam
14.7. Apellis Pharmaceuticals
14.8. Achillion Pharmaceuticals
14.9. Regeneron Pharmaceuticals
14.10. Others
Chapter 15. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Cost Analysis
15.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Key Type Analysis
15.1.1. Key Type
15.1.2. Price Trend of Key Type
15.1.3. Key Suppliers of Type
15.1.4. Market Concentration Rate of Type
15.1.5. Labor Cost
Chapter 16. Sourcing Strategy and Downstream Buyers
16.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Industrial Chain Analysis
16.2. Upstream Type Sourcing
16.3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Major Manufacturers in 2021
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Client
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Technology Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Technology Progress in Related Type
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, By Treatment, 2020 & 2027 (%)
10. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Stem Cell Transplantation, By Treatment, 2015 - 2027 (USD Million)
11. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Blood Transfusion, By Treatment, 2015 - 2027 (USD Million)
12. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Medication, By Treatment, 2015 - 2027 (USD Million)
13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, By End-User, 2020 & 2027 (%)
14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Hospitals, By End-User, 2015 - 2027 (USD Million)
15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Clinics, By End-User 2015 - 2027 (USD Million)
16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Pharmaceutical and Biotic Companies, By End-User 2015 - 2027 (USD Million)
17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Academic and Research Institutes, By End-User 2015 - 2027 (USD Million)
18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Others, By End-User 2015 - 2027 (USD Million)
19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by region, 2020 & 2027 (%)
20. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by region, 2015 - 2027(USD Million)
21. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
22. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Countries, 2020 & 2027 (%)
23. U.S. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
24. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
25. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
26. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
27. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Countries, 2020 & 2027 (%)
28. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
29. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
30. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
31. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
32. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
33. Rest of Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
34. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
35. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Countries, 2020 & 2027 (%)
36. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
37. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
38. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
39. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
40. Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
41. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
42. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market share, by Countries, 2020 & 2027 (%)
43. GCC Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
44. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
45. Rest Of Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
46. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
47. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
48. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
49. Argentina Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
50. Rest Of South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, 2015-2027 (USD Million)
4. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment requirement, by country, 2015-2027, (USD Million)
5. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Treatment, 2015-2027 (USD Million)
6. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By End-User, 2015-2027 (USD Million)
7. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Treatment, 2015-2027 (USD Million)
8. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By End-User, 2015-2027 (USD Million)
9. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Treatment, 2015-2027 (USD Million)
10. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By End-User, 2015-2027 (Revenue, USD Million)
11. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Treatment, 2015-2027 (USD Million)
12. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By End-User, 2015-2027 (USD Million)
13. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Treatment, 2015-2027 (USD Million)
14. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By End-User, 2015-2027 (USD Million)
15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Company Market Share, 2020 - 2027 (%)
16. Roche: Product Benchmarking
17. Roche: Financial Performance
18. Akari Therapeutics: Product Benchmarking
19. Akari Therapeutics: Financial Performance
20. Alexion Pharmaceuticals: Product Benchmarking
21. Alexion Pharmaceuticals: Financial Performance
22. Ra Pharmaceuticals: Product Benchmarking
23. Ra Pharmaceuticals: Financial Performance
24. Novartis Pharmaceuticals: Product Benchmarking
25. Novartis Pharmaceuticals: Financial Performance
26. Alnylam: Product Benchmarking
27. Alnylam: Financial Performance
28. Apellis Pharmaceuticals: Product Benchmarking
29. Apellis Pharmaceuticals: Financial Performance
30. Achillion Pharmaceuticals: Product Benchmarking
31. Achillion Pharmaceuticals: Financial Performance
32. Regeneron Pharmaceuticals: Product Benchmarking
33. Regeneron Pharmaceuticals: Financial Performance
The Leading Key Players in Paroxysmal Nocturnal Haemoglobinuria Market Treatment Market
Apellis Pharmaceuticals
Alexion Pharmaceuticals Inc.,hemoglobinura (PNH),
